In trials NCT02287233 and NCT03069352, venetoclax plus LDAC resulted into CR + CRi of 89% and 78%, respectively, in NPM1-mutated AML patients [77, 78]. This evidence concerns the gene NPM1 and acute myeloid leukemia.